CKD-510

CKD-510 is an orally available, first-in-class small molecule inhibitor of histone deacetylase 6 (HDAC6), developed using non-hydroxamic acid (NHA) platform technology. It was originally developed by Chong Kun Dang for the treatment of Charcot-Marie-Tooth disease (CMT), a rare hereditary peripheral nerve disorder, and has also shown preclinical efficacy in cardiovascular diseases such as atrial fibrillation, heart failure with preserved ejection fraction (HFpEF), dilated cardiomyopathy (DCM), and pulmonary arterial hypertension (PAH). The drug’s mechanism involves selective inhibition of HDAC6, which improves axonal transport in nerves and corrects abnormal protein degradation. This action has implications for both neurodegenerative and inflammatory diseases. CKD-510 received orphan drug designation from the FDA for CMT in March 2020. In November 2023, Novartis licensed global rights to develop and commercialize CKD-510 outside South Korea[2][3][5][7][8].